Celltrion biosimilar Avastin
Scope
Date
~
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)
-
Earnings
Celltrion's Q3 earnings boosted by Remsima sales in Europe
South Korean biopharmaceutical giant Celltrion Inc. announced 654.6 billion won ($478.2 million) in revenue and 213.8 billion won in operating profi...
Nov 09, 2022 (Gmt+09:00)
-
Korean stock market
Rising interest rates reshuffle Korean market cap list
Rising interest rates amid a slowing global economy rattled South Korean companies’ market capitalization rankings, bumping online players suc...
Oct 28, 2022 (Gmt+09:00)
-
Healthcare
Celltrion targets digital healthcare sector with app
Celltrion Inc., South Korea’s biopharmaceutical giant, made a foray into the digital healthcare sector for its future growth by launching a sm...
Oct 05, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins sales approval for biosimilar Vegzelma in Japan
Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...
Sep 27, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion gains sales approval for biosimilar Vegzelma in Europe
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.'s global marketing affiliate, said on Friday it has obtained the Europ...
Aug 19, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare logs record-high Q2 revenue on back of Remsima
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.’s global marketing affiliate, posted its record-high second-quar...
Aug 17, 2022 (Gmt+09:00)
-
Earnings
Celltrion logs strong Q2 earnings powered by biosimilars
South Korea’s biopharmaceutical maker Celltrion Inc. on Friday reported strong quarterly earnings thanks to healthy demand for its biosimilar ...
Aug 05, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Samsung Biologics eye record-high annual sales
South Korea’s two major biopharmaceutical companies, Celltrion Inc. and Samsung Biologics Co., are respectively expecting more than 2 trillion...
Jul 08, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...
Jun 14, 2022 (Gmt+09:00)
language -
Bio & Pharma
Celltrion to sell biosimilar products via its own channel in Europe
South Korea's biopharmaceutical company Celltrion Inc. plans to sell all of its biosimilar products through its own sales channels in Europe to impr...
May 11, 2022 (Gmt+09:00)
-
Pharmaceuticals
Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, plans to double the number of its biosimilar products on sale to 10 by 2025 and acce...
Feb 24, 2022 (Gmt+09:00)
-
Pharmaceuticals
Samsung Bioepis posts $1.26 billion in global biosimilar sales
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said on Friday that sales of its five biosimilar products in global markets, excludi...
Feb 18, 2022 (Gmt+09:00)
-
Pharmaceuticals
Celltrion, Humasis to ship $300 mn COVID-19 test kits to US
South Korea's biopharmaceutical company Celltrion Inc. and diagnostic kit manufacturer Humasis Co. have signed contracts to supply their jointly-dev...
Feb 04, 2022 (Gmt+09:00)
-
Korean stock market
EcoPro BM beats Kosdaq's top market cap Celltrion
EcoPro BM Co., a leading manufacturer of cathode material for secondary batteries, topped the market capitalization for Kosdaq-listed firms on Jan...
Jan 19, 2022 (Gmt+09:00)
language -
Pharamaceuticals, biotech
Celltrion to conduct tests on Omicron variant detected in Korea
Biopharmaceutical powerhouse Celltrion Inc. plans to use its treatments to test the Omicron variant detected in Korea, according to a high-level com...
Dec 06, 2021 (Gmt+09:00)
-
COVID-19
Celltrion to export COVID-19 treatment to Europe in 2021
South Korea’s pharmaceutical giant Celltrion Inc. is set to export its COVID-19 treatment Regkirona to Europe by the end of this year as it se...
Nov 30, 2021 (Gmt+09:00)
language -
Biotech
Celltrion looks beyond biosimilars to develop its own mRNA drugs
South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...
Nov 16, 2021 (Gmt+09:00)
-
COVID-19
Celltrion wins COVID-19 treatment approval from Europe
South Korea’s pharmaceutical giant Celltrion Inc. has won final approval for its COVID-19 treatment Regkirona from the European Commission, a ...
Nov 15, 2021 (Gmt+09:00)
language -
Biosimilars
Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz
Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...
Sep 23, 2021 (Gmt+09:00)
-
Corporate governance
Celltrion makes first step in streamlining governance structure
South Korea’s pharmaceutical conglomerate Celltrion Group has made its very first step in reforming corporate governance structure by merging ...
Sep 17, 2021 (Gmt+09:00)
language -
Biosimilars
Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe
South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...
Aug 23, 2021 (Gmt+09:00)
language -
Covid-19 treatment
Brazil gives emergency use nod for Celltrion’s COVID-19 treatment
South Korean drugmaker Celltrion Inc. has added Brazil to the list of countries that have granted emergency use approval for its COVID-19 treatment ...
Aug 13, 2021 (Gmt+09:00)
language -
COVID-19
Celltrion to enter clinical trials of new COVID-19 treatment
South Korean biosimilar maker Celltrion Inc. will launch the first-phase clinical trials of its new COVID-19 treatment candidate next month, followi...
Aug 05, 2021 (Gmt+09:00)
language -
Biosimilars
Korean drugmakers race to release Stelara biosimilars
South Korea’s major drugmakers such as Celltrion Inc., Samsung Bioepis and Dong-A St are going for broke to release biosimilars of Stelara, Jo...
Jul 22, 2021 (Gmt+09:00)
language -
Covid-19 treatment
Indonesia grants emergency use approval for Celltrion’s COVID-19 treatment
South Korean drugmaker Celltrion Inc. has received the Indonesian government’s permission for restricted use of its COVID-19 treatment Regkiro...
Jul 20, 2021 (Gmt+09:00)
-
COVID-19
Celltrion’s COVID-19 treatment reduces incidence of severity by 70%
Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by ...
Jul 13, 2021 (Gmt+09:00)
language -
Biosimilars
Celltrion, Samsung Bioepis anticipate increased biosimilar sales in Europe
South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...
Jul 12, 2021 (Gmt+09:00)
-
Medicine
Celltrion, Mirae to take largest stake in UK biotech firm
South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...
Jun 07, 2021 (Gmt+09:00)
language